EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.

Autor: Nast A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Department of Dermatology, Venereology and Allergology, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Smith C; St John's Institute of Dermatology, London, UK., Spuls PI; Academic Medical Centre Amsterdam, Amsterdam, Netherlands., Avila Valle G; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Department of Dermatology, Venereology and Allergology, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Bata-Csörgö Z; University of Szeged, Szeged, Hungary., Boonen H; Office-Based Dermatology Practice, Geel, Belgium., De Jong E; Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands., Garcia-Doval I; Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, Spain., Gisondi P; University of Verona, Verona, Italy., Kaur-Knudsen D; University Hospital Copenhagen, Copenhagen, Denmark., Mahil S; Guy's and St Thomas' NHS Foundation Trust, London, UK., Mälkönen T; Helsinki University Central Hospital, Helsinki, Finland., Maul JT; Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland., Mburu S; International Federation of Psoriasis Associations (IFPA)., Mrowietz U; Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Remenyik E; University of Debrecen, Debrecen, Hungary., Rønholt KM; Aarhus University Hospital, Aarhus, Denmark., Sator PG; Municipal Hospital Hietzing, Vienna, Austria., Schmitt-Egenolf M; Dermatology, Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden., Sikora M; Department of Dermatology, Medical University of Warsaw, Warsaw, Poland., Strömer K; Office-Based Dermatology Practice, Mönchengladbach, Germany., Sundnes O; Oslo University Hospital, Oslo, Norway., Trigos D; International Federation of Psoriasis Associations (IFPA)., Van Der Kraaij G; Academic Medical Centre Amsterdam, Amsterdam, Netherlands., Yawalkar N; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Dressler C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Department of Dermatology, Venereology and Allergology, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Feb; Vol. 35 (2), pp. 281-317.
DOI: 10.1111/jdv.16926
Abstrakt: This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
(© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: